Unlike its competitors Biontech and Moderna, the company cannot score with new corona vaccines – the former lead is lost.
(Photo: Reuters)
Frankfurt While the competitors Biontech and Moderna are bringing in double-digit billions in revenue, Tübingen-based Curevac is falling further and further behind with its Covid vaccine projects. Contrary to previous plans, the biotech company will probably not bring any new vaccine candidates into the approval process or even onto the market in the current year.
The clinical study program for a second-generation Covid vaccine, on which Curevac is working in cooperation with the British pharmaceutical company Glaxo-Smithkline (GSK), has been further delayed in recent weeks.
This is the result of a company statement published a few days ago by the US Securities and Exchange Commission (SEC). The start of a phase 1 study with the product candidate called CV2CoV, originally announced for the fourth quarter of 2021, is now planned for the first quarter of 2022. In addition, the Tübingen-based company and mRNA specialist is showing signs of a technology shift, from chemically unmodified mRNA to modified mRNA, as is also used by its competitors Biontech and Moderna.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue